Search Results - "Kavan, P"

Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions by Bender, U, Rho, Y S, Barrera, I, Aghajanyan, S, Acoba, J, Kavan, P

“…To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review…”
Get full text

Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil by Cheung, W Y, Kavan, P, Dolley, A

“…Quality of life (qol) is important for oncology patients, especially for those with late-stage disease. The present study was initiated to address the lack of…”
Get full text

Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus by Carrier, M, Blais, N, Crowther, M, Kavan, P, Le Gal, G, Moodley, O, Shivakumar, S, Tagalakis, V, Wu, C, Lee, A Y Y

“…Management of anticoagulant therapy for the treatment of venous thromboembolism (vte) in cancer patients is complex because of an increased risk of recurrent…”
Get full text

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada by Kennecke, H, Berry, S, Maroun, J, Kavan, P, Aucoin, N, Couture, F, Poulin-Costello, M, Gillesby, B

“…Selection and sequencing of treatment regimens for individual patients with metastatic colorectal cancer (mcrc) is driven by maintaining reasonable quality of…”
Get full text

A multi-institutional randomized phase II study on the timing of oxaliplatin plus 5-fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR study by Kavan, P, Barrera, I, Azoulay, L, Martin, A-G, Vasilevsky, C, Boutros, M, Ferland, E, Batist, G, Vuong, T

Get full text

Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164 by Le, D., Kavan, P., Kim, T., Burge, M., Van Cutsem, E., Hara, H., Boland, P., Van Laethem, J., Geva, R., Taniguchi, H., Crocenzi, T., Sharma, M., Atreya, C., Diaz, L., Liang, L., Marinello, P., Dai, T., O’Neill, B.

Get full text

Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy by Gambaro, K., Marques, M., McNamara, S., du Tertre, M. Couetoux, Hoffert, C., Srivastava, A., Samson, B., Lesperance, B., Ko, Y., Dalfen, R., St-Hilaire, E., Sideris, L., Couture, F., Burkes, R., Harb, M., Camlioglu, E., Gologan, A., Pelsser, V., Tejpar, S., Kavan, P., Kleinman, C., Batist, G.

Get full text

Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients by Marques, M., Gambaro, K., du Tertre, M. Couetoux, Witcher, M., Samson, B., Lesperance, B., Ko, Y., Dalfen, R., St-Hilaire, E., Sideris, L., Couture, F., Tejpar, S., Burkes, R., Harb, M., Alcindor, T., Camlioglu, E., Gologan, A., Pelsser, V., McNamara, S., Kavan, P., Kleinman, C., Batist, G.

Get full text

2354 Is pancreatic adenocarcinoma more aggressive in adolescents and young adults? A multi-institute retrospective study by Gilabert, M, Rho, Y.S, Megdanova, V, Mihaylova, Z, Rahal, S, Viens, P, Batist, G, Kavan, P

Get full text

2359 Optimal therapeutic sequences in the treatment of metastatic pancreatic cancer - a retrospective analysis from two Canadian and French tertiary cancer centres by Gilabert, M, Rho, Y.S, Kavan, T, Chanez, B, Mamo, A, Barrera, I, McLean, J, Viens, P, Batist, G, Kavan, P

Get full text

What is a clinically meaningful survival benefit in refractory metastatic colorectal cancer? by Ko, Y J, Abdelsalam, M, Kavan, P, Lim, H, Tang, P A, Vincent, M, Wong, R, Kish, M, Gill, S

“…Assessment of the clinical benefit of cancer treatments can be highly subjective, influenced by both perspective and context. Such assessments are required in…”
Get full text

Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada by Pettigrew, M, Kavan, P, Surprenant, L, Lim, H J

“…Clinical practice guidelines support the use of the epidermal growth factor receptor (EGFR) inhibitors panitumumab and cetuximab for the treatment of…”
Get more information

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment by Easaw, J C, Shea-Budgell, M A, Wu, C M J, Czaykowski, P M, Kassis, J, Kuehl, B, Lim, H J, MacNeil, M, Martinusen, D, McFarlane, P A, Meek, E, Moodley, O, Shivakumar, S, Tagalakis, V, Welch, S, Kavan, P

“…Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation therapy is used to treat vte; however, patients with cancer have…”
Get full text

Functional Neuroanatomy of Secondary Self-Injurious Behavior by Peeters, Sophie, Skoch, Jesse, Holt, Hiromi, Mubita, Lynn, Choudhary, Eileen A, Vadivelu, Kavan P, Gilbert, Donald L, Wu, Steve W, Keebaugh, Alaine C, Air, Ellen, Vadivelu, Sudhakar

“…Secondary self-injurious behavior (SSIB) is underreported and predominantly not associated with suicide. In both adults and children, SSIB can cause…”
Get more information

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis by Easaw, J C, Shea-Budgell, M A, Wu, C M J, Czaykowski, P M, Kassis, J, Kuehl, B, Lim, H J, MacNeil, M, Martinusen, D, McFarlane, P A, Meek, E, Moodley, O, Shivakumar, S, Tagalakis, V, Welch, S, Kavan, P

“…Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation therapy has been shown to prevent vte; however, unique clinical…”
Get full text

Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer by Kavan, P., Garoufalis, E., Chaudhury, P., Metrakos, P., Cabrera, T., Hausvater, A., Valenti, D., Mamo, A., Stutz, M., Steacy, G.

“…Background. Transarterial chemoembolization (TACE) has been investigated in patients with liver metastases from colorectal cancer (LMCRC). Limited experience…”
Get full text

2149 Impact of dose intensity in CAPOX and mFOLFOX6 in the treatment of metastatic colorectal cancer by Mamo, A, Rho, Y.S, Gao, Y.N, Kavan, T, McLean, J, Gilabert, M, Ivan, B, Batist, G, Chaudhury, P, Metrakos, P, Panasci, L, Kavan, P

Get full text

2054 Clinical outcomes of adolescent and young adult patients (AYAp) vs mature adult patients (MATp) with colorectal cancer (CRC), a multi-institutional retrospective review by Rho, Y.S, Gilabert, M, Barrera, I, Coleman, N, Greally, M, McDermott, R, Megdanova, V, Veneta, P, Zhasmina, M, Katerina, K, Bortlicek, Z, Pikus, T, Zdenek, L, Batist, G, Kavan, P

Get full text

Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting by Mamo, A, Easaw, J, Ibnshamsah, F, Baig, A, Rho, Y S, Kavan, T, Batist, G, Kavan, P

“…Despite lack of a true comparative study, the folfox (5-fluorouracil-leucovorin-oxaliplatin) and capox (capecitabine-oxaliplatin) regimens are believed to be…”
Get full text

Results of a Phase 2 Clinical Trial of Neo-Adjuvant Temozolomide (TMZ), Followed by Concurrent TMZ and Hypofractionated Accelerated External Beam Radiation Therapy (Ac-EBRT) With Limited Margins, and Adjuvant TMZ for Patients With Glioblastoma Multiforme (GBM) by Shenouda, G, Souhami, L, Panet-Raymond, V, Abdulkarim, B, Cury, F, Owen, S, Kavan, P, Petrecca, K, Guiot, M

Get full text